Article Text

Download PDFPDF
Allopurinol and the risk of prostate cancer
  1. Shih-Wei Lai1,2,
  2. Yu-Hung Kuo3,
  3. Kuan-Fu Liao4,5
  1. 1College of Medicine, China Medical University, Taichung, Taiwan
  2. 2Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan
  3. 3Department of Research, Taichung Tzu Chi Hospital, Taichung, Taiwan
  4. 4College of Medicine, Tzu Chi University, Hualien, Taiwan
  5. 5Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao; kuanfuliaog{at}gmail.com

Statistics from Altmetric.com

Allopurinol is commonly prescribed to treat hyperuricemia. The association between allopurinol use and other comorbidities has been widely explored.1 2 Recently one cohort study revealed that no significant association could be detected between allopurinol use and the risk of prostate cancer (HR=1.03; 95% CI 0.92 to 1.16),3 but another cohort study revealed that long-term use of allopurinol for more than 1 year was associated with a lower risk of prostate cancer in men with gout when compared with …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.